Research Program

Research Program

PDSA is dedicated to enhancing the lives of patients with Immune Thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support. In 2016, PDSA established Research Guidelines with the goal of funding the most promising research projects to further understand the pathogenesis and management of primary ITP, have the potential to raise the quality of life for ITP patients, and lead to new therapies and a cure. PDSA invites the research community to submit proposals for grants that will help us meet these goals.

Patient-Centered Research Guidelines

For Researchers

Request for Proposals Announcement provided by the Platelet Disorder Support Association for funding consideration for the research of Immune Thrombocytopenia.

Funding Announcement 2018    Proposal Template    Budget Template

Research Fund Donation

There is no cure for ITP.  Although more is known about the disease each year and new treatments have recently become available, there are many unanswered questions.  The Platelet Disorder Support Association has established a research fund to support initiatives that lead to better outcomes for the people we serve.

You can contribute to our research fund on-line or send a check or credit card number to:
Research Fund
8751 Brecksville Road, Suite 150
Cleveland, Ohio 44141
(All contributions to our research fund are tax deductible.)


Research Surveys

Bridging ITP Study

Do you have ITP and need surgery?
You may be eligible for a clinical trial in Canada comparing eltrombopag with intravenous immune globulin (IVIG) before surgery.

Inclusion criteria:

  • Primary or secondary ITP
  • Platelet count below surgical platelet count threshold (50 x109 100 x 109
  • 18 years of age or older
  • On stable doses of ITP medications
  • Surgery date is at least 3 weeks away

Exclusion criteria:

  • Pregnancy or breastfeeding
  • Treatment with IVIG within the last 2 weeks
  • Treatment with a thrombopoietin receptor agonist within the last 4 weeks
  • Liver disease, deep vein thrombosis, myocardial infarction, thrombotic stroke or arterial thrombosis in the last 12 months; active malignancy

Principal Investigator: Dr. Donald M. Arnold MD MSc (McMaster University, Hamilton, Canada)

Participating Centers:

  • Vancouver – Vancouver General Hospital
  • Edmonton – University of Alberta
  • London – London Health Sciences Centre
  • Toronto – St. Michael’s Hospital
  • Toronto – Sunnybrook Hospital
  • Ottawa – The Ottawa Hospital, General Campus
  • Montreal – Jewish General Hospital
  • Montreal – Hopital Maisonneuve-Rosemont
  • Hamilton - McMaster Hospital

For more information please contact:
Julie Carruthers, study coordinator (905-525-9140 x22942;

Non-traditional Treatments

In 2001 PDSA worked with Dr. James Bussel of the Weill Medical Center of Cornell University to develop a survey of non-traditional treatments of ITP. Almost 1,000 people responded. You can view the results HERE.

Quality of LIfe

In 2006 PDSA partnered with Amgen to design and administer a survey assessing the treatment experience and life impact of ITP. This research study led to three journal articles and a poster session at the 2008 meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Research Partners

PDSA meets regularly with directors of the National Heart Lung and Blood Institute and the Office of Rare Diseases at the National Institutes of Health and the American Society of Hematology to monitor the research progress on relevant studies and initiatives.

Research Findings

PDSA staff attend the major research conferences on thrombocytopenia and monitor scientific journals to report the latest research findings in the Newsletter and E-News.

Clinical Trials

PDSA tracks and lists the latest Clinical Trials on ITP to assure that those who want to participate are aware of these opportunities.

back to top

BBB Cleveland logoGuideStar Seal - 2017 goldNORD Member Badge 2018THSNA logo